Total Payments
$2,313
2024 Payments
$17.29
Companies
20
Transactions
33
Medicare Patients
2,799
Medicare Billing
$584,125
Payment Breakdown by Category
Consulting$1,736 (75.1%)
Food & Beverage$478.32 (20.7%)
Education$98.50 (4.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,736 | 1 | 75.1% |
| Food and Beverage | $478.32 | 29 | 20.7% |
| Education | $98.50 | 3 | 4.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $1,754 | 2 | $0 (2020) |
| Genentech USA, Inc. | $111.50 | 5 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $70.91 | 4 | $0 (2022) |
| PUMA BIOTECHNOLOGY, INC. | $45.95 | 2 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $36.10 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $35.08 | 2 | $0 (2020) |
| Medtronic, Inc. | $34.30 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $29.58 | 2 | $0 (2023) |
| Seagen Inc. | $26.22 | 1 | $0 (2022) |
| Ipsen Biopharmaceuticals, Inc | $18.86 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.29 | 1 | Medtronic, Inc. ($17.29) |
| 2023 | $36.30 | 2 | Ipsen Biopharmaceuticals, Inc ($18.86) |
| 2022 | $114.43 | 6 | Novartis Pharmaceuticals Corporation ($34.12) |
| 2021 | $69.83 | 4 | PUMA BIOTECHNOLOGY, INC. ($21.42) |
| 2020 | $1,872 | 9 | GENZYME CORPORATION ($1,754) |
| 2019 | $190.92 | 10 | Genentech USA, Inc. ($111.50) |
| 2018 | $12.29 | 1 | Seattle Genetics, Inc. ($12.29) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/13/2024 | Medtronic, Inc. | OSTEOCOOL RF ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 08/31/2023 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Oncology | ||||||
| 08/29/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.44 | General |
| Category: Oncology | ||||||
| 12/13/2022 | Medtronic, Inc. | OSTEOCOOL RF ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 10/18/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: ONCOLOGY | ||||||
| 09/15/2022 | Seagen Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $26.22 | General |
| Category: Oncology | ||||||
| 08/30/2022 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $12.55 | General |
| 04/28/2022 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2021 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: ONC | ||||||
| 10/06/2021 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA, PIQRAY | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2021 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2021 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2020 | GENZYME CORPORATION | JEVTANA (Drug) | Consulting Fee | Cash or cash equivalent | $1,736.00 | General |
| Category: Oncology | ||||||
| 06/30/2020 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: Oncology | ||||||
| 04/22/2020 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Oncology | ||||||
| 03/31/2020 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: ONCOLOGY | ||||||
| 02/25/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.14 | General |
| Category: Oncology | ||||||
| 02/18/2020 | Verastem, Inc. | Copiktra (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Hematology and Oncology | ||||||
| 02/13/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug), Nexavar, Vitrakvi | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Oncology | ||||||
| 02/11/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug), Nexavar, Vitrakvi | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Oncology | ||||||
| 01/21/2020 | AstraZeneca Pharmaceuticals LP | FASLODEX (Drug) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Oncology | ||||||
| 11/26/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $16.66 | General |
| 11/19/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: Oncology | ||||||
| 10/02/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Education | In-kind items and services | $59.99 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 609 | 1,453 | $500,806 | $129,051 |
| 2022 | 8 | 679 | 1,600 | $422,632 | $141,987 |
| 2021 | 9 | 691 | 1,724 | $462,405 | $163,537 |
| 2020 | 10 | 820 | 1,882 | $442,775 | $149,550 |
Total Patients
2,799
Total Services
6,659
Medicare Billing
$584,125
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 133 | 725 | $277,082 | $74,842 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 232 | 396 | $106,678 | $25,572 | 24.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 53 | 60 | $34,320 | $7,477 | 21.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 69 | $20,493 | $5,920 | 28.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $24,288 | $5,752 | 23.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 97 | $20,079 | $5,489 | 27.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $7,201 | $1,487 | 20.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $5,820 | $1,283 | 22.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 29 | $4,845 | $1,228 | 25.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 157 | 718 | $208,846 | $75,849 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 260 | 456 | $82,319 | $30,367 | 36.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 58 | 63 | $36,036 | $9,105 | 25.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 45 | 148 | $30,636 | $7,966 | 26.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 41 | 92 | $27,324 | $7,127 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 51 | 51 | $21,996 | $6,488 | 29.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $12,600 | $3,531 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 31 | 36 | $2,875 | $1,553 | 54.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 141 | 827 | $238,461 | $91,059 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 235 | 438 | $78,958 | $30,557 | 38.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 69 | 81 | $46,332 | $12,622 | 27.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 49 | 111 | $32,967 | $9,042 | 27.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 56 | 116 | $24,012 | $6,556 | 27.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 41 | 41 | $17,384 | $5,733 | 33.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 36 | 36 | $12,600 | $3,429 | 27.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 46 | 55 | $4,319 | $2,598 | 60.1% |
About Dr. Ryan Raddin, MD
Dr. Ryan Raddin, MD is a Hematology & Oncology healthcare provider based in Midlothian, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1659588911.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Raddin, MD has received a total of $2,313 in payments from pharmaceutical and medical device companies, with $17.29 received in 2024. These payments were reported across 33 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($1,736).
As a Medicare-enrolled provider, Raddin has provided services to 2,799 Medicare beneficiaries, totaling 6,659 services with total Medicare billing of $584,125. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Midlothian, VA
- Active Since 05/17/2007
- Last Updated 05/24/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1659588911
Products in Payments
- JEVTANA (Drug) $1,754
- TECENTRIQ (Biological) $59.99
- NERLYNX (Drug) $45.95
- ADCETRIS (Biological) $38.51
- Stivarga (Drug) $36.10
- OSTEOCOOL RF ABLATION SYSTEM (Device) $34.30
- PIQRAY (Drug) $34.12
- OPDIVO (Biological) $29.58
- Perjeta (Biological) $22.79
- FASLODEX (Drug) $20.86
- Tazverik (Drug) $18.86
- MEKINIST (Drug) $18.79
- Alecensa (Biological) $18.72
- KISQALI (Drug) $18.00
- SARCLISA (Biological) $17.72
- BLENREP (Biological) $17.44
- FOUNDATIONONE (Device) $16.73
- Beleodaq (Drug) $16.01
- CALQUENCE (Drug) $14.22
- Copiktra (Drug) $13.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.